As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the 340B Drug Pricing Program and the legal battle to stop it.

The Health Resources and Services Administration has sent a letter to Johnson & Johnson warning the company of the consequences if it proceeds with its planned 340B rebate proposal. In a Sept. 17 ...

As we look ahead to 2026, the operational demands on 340B programs are increasing across every dimension. Between the implementation of the 340B ...

The anticipated burdens on hospitals to comply with the Health Resources and Services Administration's 340B Rebate Pilot Program far exceed the agency's estimates, and HRSA should delay the program's ...

Sanofi filed a lawsuit against the Health Resources and Services Administration in federal court Dec. 16, challenging the agency’s decision to potentially remove the company from the 340B Drug Pricing ...

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

Johnson & Johnson must scrap a pharmaceutical rebate initiative for hospitals participating in the 340B Drug Discount Program or risk federal sanctions, the Health Resources and Services ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Bristol-Myers Squibb Co (NYSE:BMY) filed a lawsuit on Tuesday against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging ...

Discounted prescription drugs purchased wholesale under the 340B program grew 22.3% to $53.7 billion from 2021 to 2022, according to data published by the Health Resources and Services Administration ...